Cyclophilin A (CypA), a peptidylprolyl cis-trans isomerase, is a ubiquitous and multifunctional protein. In addition to its role as a host-cell receptor for cyclosporine A, CypA has diverse functions in inflammatory conditions and diseases. CypA secreted in response to inflammatory stimuli binds to the cell surface via its receptor CD147 and induces secretion of various inflammatory cytokines. However, silencing and inhibition of either CypA or CD147 inhibits inflammatory cytokine expression and inflammation. This report reviews the literature related to the mechanism of CypA-dependent cytokine secretion and discusses this factor as a possible therapeutic target in inflammatory diseases.
Introduction
CypA is an important member of the immunophilin family, which is ubiquitously expressed in both prokaryotic and eukaryotic cells [1] . CypA has peptidylprolyl cis-trans isomerase activity, which catalyzes protein-protein interactions and regulates protein maturation [2, 3] . The CypA protein was initially discovered as an intracellular receptor for the immunosuppressive drug cyclosporine, and the CypA-cyclosporine complex binds to and inhibits the protein phosphatase calcineurin, preventing T cell activation in mammals [4, 5] . Further, CypA is among the most abundant proteins in the cytoplasm [6] and contributes to diverse cellular functions, including immunomodulation, cell signaling, transcriptional regulation, and protein folding and trafficking [7, 8] .
Extracellular CypA influences diverse functions, including cell growth and differentiation [9] and regulates normal cell physiology [3, 10] . It is associated with various diseases, including cancer, cardiovascular diseases [11, 12] , atherosclerosis [13, 14] , and rheumatoid arthritis [15] . Moreover, it mediates inflammation in patients with gingivitis [16] and has key roles in both in acute [17] and chronic allergic [18] asthma. Extracellular CypA also functions in response to bacterial challenge [19] and frequently influences viral replication [20] .
The role of CypA in inflammation is established; it is secreted by smooth muscle cells and Mfs in response to oxidative stress and LPS [13, 21, 22] . Human platelets also secrete CypA on activation, which can contribute to the development of atherosclerosis [23] . Overall, extracellular CypA acts as a proinflammatory mediator and exerts chemotactic effects on leukocytes in various animal and cellular systems [24, 25] . Such activated leukocytes pass through junctions between endothelial cells and produce various bioactive factors, including cytokines, which promote inflammation [26] . In addition, CypA can directly mediate the secretion of cytokines from various cells; some of which are thought to contribute to different diseases [14, 27, 28] . This function of CypA has been studied extensively in recent years and is an interesting topic in the field of immunology; however, understanding of the role of CypA in cytokine secretion is incomplete. Therefore, this review focuses on the association of CypA with cytokine secretion from various cells during inflammation and the mechanism by which that occurs. This review highlights CypA as a potential therapeutic target in inflammatory diseases and encourages for further investigations.
MECHANISM OF CYPA-INDUCED CYTOKINE EXPRESSION
CypA is a secreted mediator of cytokine production. It is proinflammatory and usually secreted by leukocytes, endothelial cells, and vascular smooth muscle cells [21, 29, 30] , which guide neutrophils and eosinophils to stimulus sites, both in vitro and in vivo [31] . Extracellular CypA also has proinflammatory effects on endothelial cells through increasing their proliferation, migration, and invasion in vitro [13, 29] . Inflammatory cells express a transmembrane glycoprotein, CD147, referred to as an EMMPRIN [32] . CD147 was identified as a T cell activationassociated Ag because of its evident up-regulation in activated T cells [33] . The CD147 protein is a potent cell-surface receptor for CypA and is involved in a CypA-induced signaling cascade that terminates in ERK activation and chemotaxis [31, 34] . CypA interacts with the Pro 211 residue in the transmembrane domain of CD147 via residues in its peptidylprolyl cis-trans isomerase site and initiates signaling cascades to induce the cell-surface expression of CD147 [31, 35] . Blocking of the CD147-CypA interaction using cyclosporine A or by substitution of the Pro 211 residue of CD147 negatively affects the cell-surface expression of CD147 [31] , probably by reducing transportation of CD147 from the endoplasmic reticulum to the cell membrane by CypA [36, 37] . Cyclophilin 60, a counterpart of CypA, is also known to interact with the Pro 211 residue of CD147 and regulates the intracellular transport and cell-surface expression of CD147 [38] . The possible interaction of CypA with the Pro 180 residue of CD147 was demonstrated by reports that Pro 180 -deficient CD147
could not interact with CypA [31, 38] ; however, this substitution did not reduce the cell-surface expression of CD147, although it did eliminate the signaling response to extracellular CypA [31] . Overall, the cell-surface expression of CD147 correlates with the capacity of its transmembrane domain to interact with CypA [31] . The CypA-CD147 complex requires cell-surface heparan sulfate for optimal binding and signaling [31, 39] . The molecular structure of CD147 is different from typical chemokine receptors, such as CR, CCR, CXCR, and CX3CR; therefore, extracellular CypA may be unable to interact and synergize with chemokines [39, 40] . After the formation of a complex with CypA, truncation of the cytoplasmic tail of CD147 abrogates its signaling and chemotactic responses [41] , suggesting involvement of the cytoplasmic domain of CD147 in assembly of the signaltransducing complex [31] . The internalization of CypA into the cell and the molecular mechanism(s) by which CypA interacts with CD147 and induces intracellular signaling is unknown [25, 31] ; however in the cytoplasm, CypA binds with aa 170-176 residues (GRPLRLP) in the N-terminal domain of NF-kB subunit p65 and promotes the nuclear translocation of NF-kB [42, 43] . NF-kB is an inducible transcription factor with central roles in regulating the expression of a wide variety of genes, including inflammatory cytokines [44] . Cytoplasmic CypA also induces the ERK1/2 pathway [28, 45] ; however, mechanisms regulating the direct nuclear translocation of this transcription factor remain elusive to date. Nonetheless, CypA-stimulated ERK1/2 can activate NF-kB, which enters into the nucleus and regulates the expression of target cytokines [28] by binding to a specific-sequence motif in the promoter or enhancer region [46] (Fig. 1) .
CYPA-INDUCED CYTOKINE SECRETION
Extracellular CypA has been widely reported to stimulate the release of cytokines from Mfs in patients with rheumatoid arthritis [47] and from vascular smooth muscle cells, cardiomyocytes, and endothelial cells in vitro [29, [48] [49] [50] . Exogenous CypA increases the secretion of the Th1-type cytokines TNF-a and IFN-g from allogenic CD4 + T cells [51] , and overexpression of CypA stimulates the production of cytokine/chemokines, such as TNF-a, IL-8, MCP-1, IL-1b, and MMP-9, from THP-1 cells through a pathway dependent on NF-kB activation after LPS challenge [42] . Exogenous CypA increased the secretion of IL-5 and IL-17 in human pancreatic cancer cell lines by activation of ERK1/2 pathway, and this CypA-induced secretion of IL-5 and IL-17 could be blocked by an anti-CD147 Ab [52] . The finding that IL-17 was secreted by pancreatic cells was surprising because IL-17 was initially reported as being secreted exclusively by activated T cells, inducing stromal cells to secrete several other cytokines, including TNF-a, IL-1b, IL-6, IL-10, IL-12, IL-8, and MCP-1 [53] [54] [55] . Stable expression of CypA in the SK-Hep1 tumor cell line (human hepatocellular carcinoma) led to up-regulation of cytokines, including IL-8, IL-1b, IL-6, CXCL1, CXCL2, and CXCL3, which also decreased after CypA knockdown [56] . In atherosclerotic mice, extracellular CypA caused overexpression of MCP-1 and IL-6 from vascular smooth muscle cells in both atherosclerotic plaques and in tunica media [14] . In atherosclerotic APOE null mice, CypA increased IL-6 expression in Figure 1 . A schematic model of CypA induced cytokine secretion. Extracellular CypA binds to the cell surface receptor, CD147, which results in internalization of CypA and stimulates a downstream cascade leading to independent activation of ERK1/2 or NF-kB. Whether ERK1/2 localizes directly to the nucleus is unknown; however, ERK1/2 activates NF-kB in the cytoplasm, which localizes to the nucleus and activates the target cytokine genes indicated in the figure. endothelial cells and vascular smooth muscle cells [57] . AntiCypA single-domain Ab significantly reduced the levels of the human inflammatory cytokines IL-6 and IL-8 in mice with collagen-induced arthritis. In vitro data demonstrated that singledomain Ab could counteract CypA-dependent MMP-9 secretion and IL-8 production by interfering with the ERK-NF-kB pathway [28] . In another recent experiment, CypA was found to significantly increase the protein and transcript expression of VCAM-1, MMP-9, IL-6, and TNF-a in apolipoprotein E-deficient mice with atherosclerotic plaques [58] . In acinar cells from a mouse with acute pancreatitis, recombinant CypA significantly increased the expression of cytokines, including IL-1b, IL-6, TNFa, and CXCL-1, via the NF-kB pathway [59] . Moreover, CypA induced significantly greater expression of IL-6, IL-8, IL-12p40, and MCP-2 levels in patients with tuberculosis [60] .
Enforced expression of CypA markedly enhanced levels of IL-8 transcription in human glioblastoma cell lines, and that expression was reduced by knockdown of CypA and subsequent diminished activity of NF-kB [61] . Purified CypA significantly increased the production of IL-6, IL-8, TNF-a, and MMP-9 in THP-1 monocytes through the NF-kB and ERK1/2 pathways [48, 62] ; however, blocking EMMPRIN via specific small interfering RNA or Abs, inhibited both cytokine production and NF-kB expression [48, 62] . Recombinant human CypA significantly induced IL-8, MMP-2, and MMP-9 production from THP-1 monocytes [15] . The increased expression of CypA during Edwardsiella ictaluri infection in yellow catfish led to increased expression of IL-1b and TNF-a in the liver, head, kidney, and spleen [63] . Together, these publications provide evidence of a significant role for CypA in aberrant expression of cytokines through the NF-kB-mediated signaling pathway. Moreover, these data highlight CypA as a promising therapeutic target in pathologic conditions and inflammatory diseases.
CONCLUSION AND PERSPECTIVES
CypA secreted in response to inflammatory stimuli is a potent mediator of cytokine production by numerous cell types, whereas inhibition of CypA or its receptor CD147 results in inhibition of cytokine secretion. Hence, CypA is a potential therapeutic target in numerous inflammatory diseases. The cytokines released from leukocytes are involved in the pathogenesis of harmful diseases [27, 56, 64] , and up-regulation of cytokines can lead to a neoplastic microenvironment that may confer a growth advantage on tumor cells [56] . Production of these CypA-stimulated cytokines can arise through a pathway dependent on ERK1/2 and NF-kB activation; however, the precise mechanisms underlying CypA-mediated stimulation of the ERK1/2 and NF-kB pathways remain unclear and require further investigation. Once the exact processes involved in CypA-mediated signaling are established, efforts to explore mechanisms to safely inhibit CypA or other associated factors are warranted to treat a wide range of inflammatory diseases. 
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